Erasca stock heads toward November cancer data presentations

Published on 10/07/2026 at 00:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Erasca stock was last at USD 14.30 on October 6, 2026, 41.1 percent below its 52-week high. Eleven brokerages set a USD 22.09 average target.

ERAS, US29479A1088, Illustration mit AI erstellt.

Erasca stock (ISIN US29479A1088) was last at USD 14.30 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 2.85 percent from the prior close. The clinical-stage oncology company is heading toward updated clinical data presentations for ERAS-0015 at the ENA Symposium beginning November 18, 2026.

November brings updated cancer data

According to Erasca in its September 10, 2026 release, the company will present updated monotherapy data from the ongoing Phase 1 AURORAS-1 trial of ERAS-0015. A separate poster will cover nonclinical combination data for ERAS-0015 and ERAS-4001 in KRAS G12X-driven models.

The company scheduled the symposium for November 18 through November 20, 2026, in Barcelona. For investors, the important variable is the expansion of the ERAS-0015 dataset, because the presentation is intended to add patients and longer follow-up to earlier results.

Consensus target reaches USD 22.09

MarketBeat reported on October 3, 2026 that 11 brokerages held a Moderate Buy consensus, comprising eight Buy, two Hold and one Sell rating. The average 12-month price target was USD 22.09, which stands 54.5 percent above the USD 14.30 price on October 6, 2026.

The range of views remains wide. HC Wainwright raised its target from USD 18.00 to USD 22.00 on August 12, 2026, while Bank of America lifted its target from USD 18.00 to USD 20.00 on August 14, 2026, according to MarketBeat.

Q2 loss missed the estimate

MarketBeat said Erasca reported adjusted EPS of negative USD 0.14 for Q2 2026 on August 11, 2026, versus a consensus loss of USD 0.11. The USD 0.03 miss keeps clinical progress and financing capacity central to the valuation discussion.

Erasca's September 10 release also identified clinical timing, regulatory requirements and patent litigation as risks to the development program. The company is advancing ERAS-0015 and ERAS-4001 as precision medicines aimed at cancers driven by the RAS/MAPK pathway.

Price stays below the yearly high

At USD 14.30 on October 6, 2026, Erasca's market capitalization was USD 5.0 billion and the stock stood 41.1 percent below its 52-week high of USD 24.28. Its 52-week low was USD 2.10, leaving the current price closer to the upper end of the annual range than to the low.